公开(公告)号：US20240277838A1

公开(公告)日：2024-08-22

申请号：US18659241

申请日：2024-05-09

Applicant: GENENTECH, INC.

Inventor： Gail Lewis Phillips ,  Deepak Sampath ,  Ingrid Wertz

IPC: A61K39/395 ,  A61K31/496 ,  A61K31/635 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32 ,  G01N33/574

CPC classification number: A61K39/39558 ,  A61K31/496 ,  A61K31/635 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6851 ,  A61P35/00 ,  C07K16/32 ,  G01N33/57415 ,  G01N33/57446 ,  A61K2039/505 ,  A61K2300/00 ,  C07K2317/24 ,  C07K2317/73 ,  G01N2333/4703 ,  G01N2800/52

Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

公开(公告)号：US20220265642A1

公开(公告)日：2022-08-25

申请号：US17709324

申请日：2022-03-30

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US11413282B2

公开(公告)日：2022-08-16

申请号：US15365595

申请日：2016-11-30

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother

IPC: A61K31/496 ,  A61P35/02 ,  A61P35/00

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US10898570B2

公开(公告)日：2021-01-26

申请号：US15849018

申请日：2017-12-20

Applicant: Genentech, Inc.

Inventor： Gail Lewis Phillips ,  Deepak Sampath ,  Ingrid Wertz

IPC: A61K39/395 ,  C07K16/32 ,  G01N33/574 ,  A61K47/68 ,  A61K31/635 ,  A61K45/06 ,  A61P35/00 ,  A61K31/496 ,  A61K39/00

Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

公开(公告)号：US09855270B2

公开(公告)日：2018-01-02

申请号：US14645578

申请日：2015-03-12

Applicant: Genentech, Inc.

Inventor： Jeffrey J. Hager ,  James D. Joseph ,  Jing Qian ,  Nicholas D. Smith ,  Edna Chow Maneval ,  Debasish F. Roychowdhury ,  Lori Friedman ,  Deepak Sampath

IPC: A61K31/5375 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4025 ,  A61K31/397 ,  C12Q1/68

CPC classification number: A61K31/5375 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  C12Q1/6886 ,  C12Q2600/156

Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.

公开(公告)号：US20170281619A1

公开(公告)日：2017-10-05

申请号：US15365595

申请日：2016-11-30

Applicant: GENENTECH, INC. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother

IPC: A61K31/496

CPC classification number: A61K31/496 ,  A61K2300/00

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20170157124A1

公开(公告)日：2017-06-08

申请号：US15438277

申请日：2017-02-21

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Michelle Nannini ,  Elizabeth Punnoose ,  Deepak Sampath ,  Jeffrey Wallin ,  Premal Patel

IPC: A61K31/517 ,  A61K31/337

CPC classification number: A61K31/517 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4166 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/58 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07D239/70 ,  C07D403/12 ,  C07K16/40 ,  A61K2300/00

Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

公开(公告)号：US20160045515A1

公开(公告)日：2016-02-18

申请号：US14791783

申请日：2015-07-06

Applicant: Genentech, Inc.

Inventor： Marcia Belvin ,  Lori Friedman ,  Deepak Sampath ,  Jeffrey Wallin

IPC: A61K31/553 ,  C12Q1/68 ,  A61K45/06

CPC classification number: A61K31/553 ,  A61K31/138 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4523 ,  A61K31/513 ,  A61K31/555 ,  A61K31/565 ,  A61K31/573 ,  A61K31/7068 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5023 ,  A61K2300/00

Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.

Abstract translation: 提供了用于治疗患有PI3K抑制剂，GDC-0032作为单一药剂或与化学治疗剂组合的患者中的过度增殖性疾病的方法和组合物。

公开(公告)号：US20150258099A1

公开(公告)日：2015-09-17

申请号：US14645578

申请日：2015-03-12

Applicant: Genentech, Inc.

Inventor： Jeffrey J. Hager ,  James D. Joseph ,  Jing Qian ,  Nicholas D. Smith ,  Edna Chow Maneval ,  Debasish F. ROYCHOWDHURY ,  Lori Friedman ,  Deepak Sampath

IPC: A61K31/5375 ,  A61K31/4245 ,  C12Q1/68 ,  A61K31/437 ,  A61K31/4025 ,  A61K31/397 ,  A61K31/416 ,  A61K31/428

CPC classification number: A61K31/5375 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  C12Q1/6886 ,  C12Q2600/156

Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.

Abstract translation: 本文描述了通过施用雌激素受体调节剂治疗特征在于ESR1基因突变的ER相关疾病状态的方法和组合物。 本文还描述了通过施用雌激素受体调节剂治疗特征在于ESR1基因突变的激素抵抗 - 雌激素受体（ER）阳性乳腺癌的方法。

公开(公告)号：US20150258080A1

公开(公告)日：2015-09-17

申请号：US14645585

申请日：2015-03-12

Applicant: Genentech, Inc.

Inventor： Jeffrey J. Hager ,  Edna Chow Maneval ,  Nicholas D. Smith ,  Lori Friedman ,  Deepak Sampath

IPC: A61K31/4439 ,  A61K31/553 ,  A61K31/5377 ,  A61K31/397 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/4025 ,  A61K45/06 ,  A61K31/517

CPC classification number: A61K31/4439 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/416 ,  A61K31/4188 ,  A61K31/424 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  A61K2300/00

Abstract: Described herein are therapeutic combinations with estrogen receptor modulators for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract translation: 本文描述的是用于治疗介导或依赖于雌激素受体的疾病或病症的雌激素受体调节剂的治疗组合。